

**Medical Procedures*****TXA Administration*****Date: 07/01/2023****Policy #7150****I. Purpose:**

- A. To establish indications, guidelines, and the standard procedures for administering Tranexamic Acid (TXA) in patients with known or suspected life or limb-threatening bleeding.

**II. Authority:**

- A. Health and Safety Code, Section 1797.220, 1798. Title 22, Section 100170.

**III. Policy:**

- A. TXA may be administered under the following indications:

1. Patient had blunt or penetrating trauma with signs of poor perfusion, including, but not limited to:
  - a. Systolic blood pressure < 90 mmHg
  - b. Sustained tachycardia
  - c. Abnormal skin findings
  - d. Altered mental status
2. Partial or complete amputation proximal to wrist or ankle that is not controllable with 2 tourniquets, direct pressure and packing
3. Earlier interventions from the **Hemorrhage Control Policy** have been unsuccessful
4. Uncontrollable postpartum hemorrhage within three hours of delivery

- B. Contraindications for TXA:

1. Patients with known or active thromboembolic events or disease
  - a. Stroke
  - b. Myocardial infarction
  - c. Pulmonary embolism or deep venous thrombosis
2. Allergy or sensitivity to TXA
3. Greater than three hours from hemorrhage onset
4. Age less than 15 years old

- C. Document the following in the patient care record:

**Medical Procedures****TXA Administration****Date: 07/01/2023****Policy #7150**

1. Signs and symptoms indicating need for medication
  2. Suspected complications or side effects from treatment
  3. Response to treatment
- D. It is crucial at time of hand-off to receiving facility, use of TXA is reported to receiving facility to ensure the second dose of TXA is administered in a timely fashion

**IV. Procedure:**

- A. Adults (patients aged 15 years old or older): Mix 1 gram of TXA in a 100 ml bag of 0.9% NaCl and infuse over 10 minutes via IV or IO.
- B. Monitor patients for adverse side effects including:
  1. Acute gastrointestinal disturbances
  2. Visual disturbances (blurry vision and changes in color perception, especially with prolonged use)
  3. Sudden shortness of breath or chest pain
  4. Dizziness, fatigue, headache, and hypersensitivity reaction
  5. Seizures

**V. Quality Assurance:**

- A. All TXA administrations will undergo review by provider agency, the Imperial County EMS QA review and standard data elements shall be reported.

APPROVED:

Signature on File

Katherine Staats, M.D. FACEP  
EMS Medical Director

